US Patent Issued to TUDAG TU Dresden on March 31 for "Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects" (American, German Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,963, issued on March 31, was assigned to TUDAG TU Dresden AG (Dresden, Germany).

"Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects" was invented by Andreas Androutsellis-Theotokis (Dresden, Germany) and Steven Walter Poser (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides methods of screening a subject for a proliferative disease risk factor which comprises detecting the presence or absence of target cells. The presence of target cells in the subject indicates the subject is at increased risk of developing a proliferative disease or recurrence of a previously treated p...